Products — Brontec Plus

Brontec Plus

Clenbuterol + Bromhexine


  • Maximum effectiveness against respiratory diseases.
  • Mucolytic, decreases the viscosity of the mucus.
  • Secretolytic, increases the speed of elimination of the bronchial mucus.
  • Expectorant, increases bronchial secretions abroad.
  • Strengthens the body's defenses by increasing the level of gamma globulins.
  • Increases the concentration of antibiotics in the pulmonary secretion 2 to 3 times, when administered simultaneously.
  • Antitussive, calms irritative cough.


The product is a combination of a bronchodilator and a mucolytic and expectorant, indicated for horse respiratory diseases.


Clenbuterol 0,04 mg
Bromhexine 1,25 g


For the treatment of respiratory infections and bronchial obstructions that present with mucus accumulation and/or bronchospasm with acute and chronic conditions in horses: Cough and dyspnea due to bronchial spasm, COPD, Bronchitis, Bronchopneumonia.

Brontec Plus also stimulates mucociliary cleaning.

Combination treatment with antibiotics and/or sulfonamides is indicated in acute cases of bronchitis and bronchopneumonia.

Therapeutic Action:

Brontec Plus Clenbuterol has the following actions:

Bronchodilator action: it acts at the level of the beta receptors of the bronchial muscles, solving the reversible bronchospasm, increasing the air passage and normalizing breathing.

Expectorant action: increases secretomotor activity (ciliary movement), by increasing cellular energy metabolism promoting the elimination of mucus.

Antiallergic action: prevents the release of histamine by stabilizing the cell membrane of mast cells.

Anti-inflammatory action: inhibits the formation of inflammation mediators (Prostaglandins and Leukotrins), helping to control inflammatory symptoms.

Brontec Plus Bromhexine: Produces a depolymerization of mucopolysaccharides, reducing the viscosity and toughness of the respiratory mucus. This facilitates expectoration and suppresses irritative cough. The increased production of viscous bronchial and alveolar secretions is not only a clinical sign of respiratory disease, but an exacerbating factor of it. Disordered ciliary function and difficulty in expectoration establish a vicious circle in which mucous toughness leads to chronic bronchitis. Bromhexine is a specific agent to prevent this complication. It has a minimal secretolytic effect when the mucous viscosity is initially low. Increases the permeability of the alveolar-capillary barrier. This increases the concentration of antimicrobial agents in the respiratory secretions, obtaining a greater dose effect at the level of the injury site. It causes changes in the specific proteins of the bronchial secretion. After 2 to 3 days of treatment, there is a significant increase in gamma globulins and a decline in albumins and alpha globulins. The increased gamma globulins are IgA and IgG, while IgM remains unchanged.

Dosage and Administration:

Administer orally 2 ml of the gel every 100 kg b.w. twice daily.

After an obvious improvement, the volume or the number doses per day can be reduced. The duration of treatment depends on a considerable number of factors related to the disease, etiology, duration of the process, etc. that the treating practitioner will evaluate appropriately.

In acute and subacute cases the treatment will be maintained for 10 to 14 days. In chronic processes, it will be treated for at least 4 weeks until total symptoms are absent. In patients hypersensitive to environmental allergens, treatment can be administered discontinuously.




Bottle of 500 ml.